Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review.
Research article published in Pharmacotherapy (2021)
Abstract
The use of direct-acting oral anticoagulants (DOACs) has increased secondary to the mounting evidence for comparable efficacy and potentially superior safety to vitamin K antagonists (VKAs) in the general population. However, insufficient data regarding DOAC use in solid organ transplant (SOT) recipients and numerous pharmacokinetic and pharmacodynamic considerations limit their use in this highly selected patient population. A systematic review of recent clinical evidence on the safety and efficacy of DOACs compared to VKAs in SOT recipients was conducted. Additional considerations including transplant-specific strategies for DOAC reversal and common pharmacokinetic/pharmacodynamic concerns were also reviewed. Although current evidence is limited to single-center retrospective analyses, DOACs, especially apixaban, appear to be a safe and effective alternative to VKAs for SOT recipients with stable graft function and without drug-drug interactions. Reliable data on DOAC reversal at the time of transplant surgery are lacking, and clinicians should consider idarucizumab, andexanet alfa, and other non-specific reversal agents on an individual patient basis. There is no evidence supporting deviations from the Food and Drug Administration labeling recommendations for DOAC dosing in the setting of drug-drug interactions, obesity, and renal function, especially in patients on hemodialysis.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review.
Why This Matters for Hirudotherapy
This systematic review examined the safety and efficacy of direct-acting oral anticoagulants (DOACs) versus vitamin K antagonists in solid organ transplant recipients and concluded that, based on limited single-center retrospective data, DOACs (especially apixaban) appear to be a safe and effective alternative in patients with stable graft function and no drug-drug interactions, while noting that reliable data on DOAC reversal at the time of transplant surgery are lacking. Its relevance to hirudotherapy is contextual rather than direct: it documents both the appeal and the persistent pharmacologic limitations (reversal agents, drug interactions, narrow data) of synthetic anticoagulants, the broader clinical problem space in which leech-derived antithrombotics such as hirudin are studied as natural thrombin inhibitors. Honest caveat: the review concerns oral synthetic drugs in transplant patients, contains no leech or hirudotherapy content, and the authors themselves stress that the underlying evidence is limited to small retrospective analyses.
Citation
Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review.
Bixby et al. · Pharmacotherapy, 2021
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026